DG Capital Management (Massachusetts)’s Vertex Pharmaceuticals VRTX Stock Holding History

DG Capital Management (Massachusetts)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$536K	Sell	6,144 -2,980	-33%	-$282K	0.53%	57
2016 Q2	$785K	Buy	9,124 +2,251	+33%	+$195K	0.84%	52
2016 Q1	$546K	Sell	6,873 -900	-12%	-$81.4K	0.53%	57
2015 Q4	$978K	Sell	7,773 -3,830	-33%	-$462K	0.87%	46
2015 Q3	$1.21M	Sell	11,603 -1,820	-14%	-$234K	0.81%	48
2015 Q2	$1.66M	Sell	13,423 -545	-4%	-$68.7K	1%	49
2015 Q1	$1.65M	Buy	13,968 +8,215	+143%	+$984K	0.99%	50
2014 Q4	$683K	Sell	5,753 -2,540	-31%	-$286K	0.4%	60
2014 Q3	$931K	Buy	8,293 +3,203	+63%	+$305K	0.57%	58
2014 Q2	$482K	Sell	5,090 -15,020	-75%	-$1.05M	0.27%	58
2014 Q1	$1.42M	Sell	20,110 -8,215	-29%	-$651K	0.84%	48
2013 Q4	$2.1M	Sell	28,325 -9,215	-25%	-$642K	1.17%	44
2013 Q3	$2.85M	Buy	37,540 +2,500	+7%	+$199K	1.61%	32
2013 Q2	$2.81M	Buy	+35,040	New	+$2.58M	1.7%	29

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DG Capital Management (Massachusetts)'s VRTX Position: Q3 2016 in Review

DG Capital Management (Massachusetts) reduced its Vertex Pharmaceuticals (VRTX) stake by 33% in Q3 2016, selling an estimated $282K and leaving 6,144 shares worth $536K. The position accounts for 0.53% of the portfolio, ranked #57.

DG Capital Management (Massachusetts) first reported a position in VRTX in Q2 2013 and has held it in 14 quarters since. The position peaked at $2.85M in Q3 2013. 489 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

DG Capital Management (Massachusetts) held 6,144 shares of Vertex Pharmaceuticals worth $536K as of Q3 2016.
DG Capital Management (Massachusetts) sold 2,980 Vertex Pharmaceuticals shares in Q3 2016, an estimated $282K.
Vertex Pharmaceuticals made up 0.53% of DG Capital Management (Massachusetts)'s portfolio in Q3 2016, its #57 holding.
DG Capital Management (Massachusetts) first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
DG Capital Management (Massachusetts)'s Vertex Pharmaceuticals position peaked at $2.85M in Q3 2013.
489 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q3 2016, filed 21 Oct 2016.